HPV DNA status and clinical history of patients are supplements for accurate reporting of the cytological Pap smear.
Cervical cancer
HPV
Pap smear
Squamous Intraepithelial lesion-SIL
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
17
03
2024
accepted:
22
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
The present study was aimed at showing the importance of HPV DNA status and the clinical history of the patients required by the cytologist for accurate reporting. A total of 1250 symptomatic women who attended the gynaecology outpatient department of the Mahavir Cancer Sansthan and Nalanda Medical College, Patna, for pap smear examinations were screened and recruited for the study. Due to highly clinical symptoms out of the negative with inflammatory smears reported, one hundred and ten patients were randomly advised for biopsy and HPV 16/18 DNA analysis by a gynaecologist to correlate negative smears included in the study. Pap smear reports revealed that 1178 (94.24%) were negative for intraepithelial lesions (NILM) with inflammatory smears, 23 (1.84%) smears showed low-grade squamous intraepithelial lesions (LSIL), 12 (0.96%) smears showed high-grade squamous intraepithelial lesions, and 37 (2.96%) smears showed an atypical squamous cell of undetermined significance (ASC-US). A biopsy of 110 out of 1178 (NILM) patients revealed that 15 (13.63%) women had cervical cancer, 29 women had CIN I, 17 women had CIN II + CIN III, 35 women had benign cervical changes, and 14 women had haemorrhages. On the other hand, HPV 16/18 DNA was detected as positive in 87 out of 110. The high positivity of HPV in biopsied cases where frank cervical cancer and at-risk cancer were also observed in the negative smear-screened patients reveals that the HPV status and clinical history of the patients will be quite helpful to the cytologist for accurate reporting, and suggests that a negative HPV DNA result may be a stronger predictor of cervical cancer risk than a negative Pap test.
Identifiants
pubmed: 39080413
doi: 10.1038/s41598-024-68344-4
pii: 10.1038/s41598-024-68344-4
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17486Informations de copyright
© 2024. The Author(s).
Références
Sung, H., Ferlay, J. & Siegel, R. L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(03), 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Bhattacharyya, A. K., Nath, J. D. & Deka, H. Comparative study between pap smear and visual inspection with acetic acid (VIA) in screening of CIN and early cervical cancer. J. Midlife. Health 6, 53–58 (2015).
pubmed: 26167054
pmcid: 4481740
Bobdey, S. et al. Cancer screening: should cancer screening be essential component of primary health care in developing countries?. Int. J. Prev. Med. 6, 56–65 (2015).
doi: 10.4103/2008-7802.160053
pubmed: 26236443
pmcid: 4505397
Karimi-Zarchi, M. et al. Comparison of Pap smear and colposcopy in screening for cervical cancer in patients with secondary immunodeficiency. Electron. Phys. 7, 1542–1548 (2015).
Nayar, R. & Wilbur, D. C. The Pap test and bethesda 2014. Acta Cytol. 59, 121–132. https://doi.org/10.1159/000381842 (2015).
doi: 10.1159/000381842
pubmed: 25997404
Ruba, S., Schoolland, M., Allpress, S. & Sterrett, G. Adenocarcinoma in situ of the uterine cervix: Screening and diagnostic errors in Papanicolaou smears. Cancer 102, 280–287. https://doi.org/10.1002/cncr.20600 (2004).
doi: 10.1002/cncr.20600
pubmed: 15376198
Schoolland, M., Allpress, S. & Sterrett, G. F. Adenocarcinoma of the cervix. Cancer 96, 5–13. https://doi.org/10.1002/cncr.10313 (2002).
doi: 10.1002/cncr.10313
pubmed: 11836697
Castanon, A., Landy, R. & Sasieni, P. D. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?. Int. J. Cancer. 139, 1040–1045. https://doi.org/10.1002/ijc.30152 (2016).
doi: 10.1002/ijc.30152
pubmed: 27096255
pmcid: 4915496
Bulk, S. et al. High-risk human papillomavirus is present in cytologically false-negative smears: An analysis of “normal” smears preceding CIN2/3. J. Clin. Pathol. 61, 385–389. https://doi.org/10.1136/jcp.2006.045948 (2008).
doi: 10.1136/jcp.2006.045948
pubmed: 17675539
Komerska, K. et al. Why are Polish women diagnosed with invasive cervical cancer after negative cytology in the organized screening programme—A pilot reevaluation of negative Pap smears preceding diagnoses of interval cancers. Pol. J. Pathol. 72, 261–266. https://doi.org/10.5114/pjp.2021.112832 (2021).
doi: 10.5114/pjp.2021.112832
pubmed: 35048639
Sankaranarayanan, R. Screening for cancer in low- and middle-income countries. Ann. Global Health 80(5), 412–417. https://doi.org/10.1016/j.aogh.2014.09.014 (2014).
doi: 10.1016/j.aogh.2014.09.014
Brinkmann, D., Gladman, M. A., Norman, S. & Lawton, F. G. Why do women still develop cancer of the cervix despite the existence of a national screening programme?. Eur. J. Obstetrics Gynecol. Reproductive Biol. 119(1), 123–124. https://doi.org/10.1016/j.ejogrb.2004.07.021 (2005).
doi: 10.1016/j.ejogrb.2004.07.021
Khuhaprema, T. et al. Organization and evolution of organized cervical cytology screening in Thailand. Int. J. Gynaecol. Obstet. Off. Organ Int. Feder. Gynaecol. Obstetrics 118(2), 107–111. https://doi.org/10.1016/j.ijgo.2012.03.031 (2012).
doi: 10.1016/j.ijgo.2012.03.031
Reeves, W. C., Brinton, L. A., Garcia, M. & Brenes, M. M. Human papillomavirus infection and cervical cancer in Latin America. N. Engl. J. Med. 320(22), 1437–1441 (1989).
doi: 10.1056/NEJM198906013202201
pubmed: 2541336
Bosch, F. X. et al. Risk factors for cervical cancer in Columbia and Spain. Int. J. Cancer 52, 750–758 (1992).
doi: 10.1002/ijc.2910520514
pubmed: 1330934
Eluf-Neto, J. et al. Human papillomavirus and invasive cervical cancer in Brazil. Br. J. Cancer 69, 114–119 (1994).
doi: 10.1038/bjc.1994.18
pubmed: 8286192
pmcid: 1968795
Kouri, M. T. et al. HPV prevalence among Mexican women with neoplastic and normal cervices. Gynaecol. Oncol. 70, 115–120 (1998).
doi: 10.1006/gyno.1998.5055
Chinchareon, S. et al. Risk factors for cervical cancer in Thailand: A case control study. J. Natl. Cancer Inst. 90(1), 50–57 (1998).
doi: 10.1093/jnci/90.1.50
Bosch, F. X., Munoz, N. & Sanjose, S. D. Human papillomavirus and the other risk factors for cervical cancer. Biomed. Pharmacother. 51, 268–275 (1997).
doi: 10.1016/S0753-3322(97)83542-1
pubmed: 9309247
Walboomers, J. M., Jacobs, M. V. & Manos, M. M. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12–19 (1999).
doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
pubmed: 10451482
Bosch, F. X. & de Sanjose, S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31, 3–13 (2003).
Das, B. C., Gopalkrishna, V. & Das, D. K. Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. Cancer 72(1), 147–153 (1993).
doi: 10.1002/1097-0142(19930701)72:1<147::AID-CNCR2820720128>3.0.CO;2-7
pubmed: 8389665
Iwasawa, A., Nieminen, P., Lehtinen, M. & Paavonen, J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 77(11), 2275–2279 (1996).
doi: 10.1002/(SICI)1097-0142(19960601)77:11<2275::AID-CNCR14>3.0.CO;2-U
pubmed: 8635095
Das, B. C., Sharma, J. K., Gopalakrishna, V. & Luthra, U. K. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J. Gen. Virol. 73, 2327–2336 (1992).
doi: 10.1099/0022-1317-73-9-2327
pubmed: 1328489
Kailash, U., Soundararajan, C. C. & Lakshmy, R. Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer. Br. J. Cancer 95(9), 1250–1257 (2006).
doi: 10.1038/sj.bjc.6603375
pubmed: 17060942
pmcid: 2360573
Pande, S., Jain, N. & Prusty, B. K. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J. Clin. Microbiol. 46(3), 1060–1066 (2008).
doi: 10.1128/JCM.02202-07
pubmed: 18199779
pmcid: 2268386
Bhatla, N., Dar, L. & Rajkumar, P. A. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int. J. Gynecol. Pathol. 27(3), 426–430 (2008).
doi: 10.1097/PGP.0b013e31816085ba
pubmed: 18580322
pmcid: 4156035
Bhatla, N., Dar, L. & Patro, A. R. Human papillomavirus type distribution in cervical cancer in Delhi. India. Int. J. Gynecol. Pathol. 25(4), 398–402 (2006).
doi: 10.1097/01.pgp.0000209574.62081.e4
pubmed: 16990719
Franceschi, S., Rajkumar, T. & Vaccarella, S. Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case–control study. Int. J. Cancer. 107(1), 127–133 (2003).
doi: 10.1002/ijc.11350
pubmed: 12925967
Sowjanya, A. P., Jain, M. & Poli, U. R. Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh. India. BMC Infect. Dis. 5, 116 (2005).
doi: 10.1186/1471-2334-5-116
pubmed: 16371167
Nanda, K. et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann. Intern. Med. 132, 810–819. https://doi.org/10.7326/0003-4819-132-10-200005160-00009 (2000).
doi: 10.7326/0003-4819-132-10-200005160-00009
pubmed: 10819705
Mustafa, R. A. et al. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int. J. Gynecol. Obstet. 132, 259–265. https://doi.org/10.1016/j.ijgo.2015.07.024 (2016).
doi: 10.1016/j.ijgo.2015.07.024
Anttila A., Arbyn M., De Vuyst H., Dillner J., Dillner L., Franceschi S., Patnik J., Ronco G., Segnan N. & Suinio E. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. International Agency for Research on Cancer; Lyon, France: (2008). [Google Scholar]
Austin, R. M. & Zhao, C. Observations from Pap litigation consultations. Pathol. Case Rev. 16(2), 73–82. https://doi.org/10.1097/PCR.0b013e31820fff8a (2011).
doi: 10.1097/PCR.0b013e31820fff8a
Frable, W. J. Error reduction and risk management in cytopathology. Semin. Diagnostic Pathol. 24(2), 77–88. https://doi.org/10.1053/j.semdp.2007.03.006 (2007).
doi: 10.1053/j.semdp.2007.03.006
Zhao, C., Florea, A., Onisko, A. & Austin, R. M. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol. Oncol. 114(3), 383–389. https://doi.org/10.1016/j.ygyno.2009.05.019 (2009).
doi: 10.1016/j.ygyno.2009.05.019
pubmed: 19501894
Fernandes, J. V. et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol. Lett. 9(3), 1015–1026. https://doi.org/10.3892/ol.2015.2884 (2015).
doi: 10.3892/ol.2015.2884
pubmed: 25663851
pmcid: 4315066
Deivendran, S., Marzook, K. H. & Pillai, M. R. The role of inflammation in cervical cancer. InInflammation and cancer 377–399 (Springer, Basel, 2014).
Hemmat, N. & Bannazadeh, B. H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathogens Dis. 77(5), ftz048 (2019).
doi: 10.1093/femspd/ftz048
Koliopoulos, G. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 8, CD008587. https://doi.org/10.1002/14651858.CD008587.pub2 (2017).
doi: 10.1002/14651858.CD008587.pub2
pubmed: 28796882